ClinicalTrials.Veeva

Menu

Therapeutic Study Evaluating the Efficacy of Noradrenaline in the Prevention of Hypotension Related to Intubation for Cardiac or Thoracic Surgery (EPITUBE-HEART)

N

Nantes University Hospital (NUH)

Status and phase

Completed
Phase 3

Conditions

Hypotension
Cardiac Disorder

Treatments

Drug: noradrenaline

Study type

Interventional

Funder types

Other

Identifiers

NCT05335954
RC21_0144

Details and patient eligibility

About

Arterial hypotension during general anaesthesia (GA) is a serious event. While hypotension can occur during surgery, it usually occurs following induction of GA (i.e. following the injection of drugs to enable intubation). This is due to the injection of large doses of anaesthetic drugs with a vasodilatory effect over a short period of time to induce a deep sleep to allow intubation to take place for artificial ventilation.

The prevention of hypotension during surgery has been extensively studied. In contrast, the prevention of hypotension following GA induction has been the subject of only two randomised studies in the ICU and three non-randomised studies in the OR with small numbers of patients. The level of evidence for the use of noradrenaline in the operating theatre remains low.

The hypothesis of the study is that noradrenaline initiated during preoxygenation can reduce the incidence of hypotension during induction of general anaesthesia.

Enrollment

211 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Requiring cardiac or thoracic surgery under general anaesthesia
  • Requiring a blood pressure catheter prior to GA induction

Exclusion criteria

  • Hemodynamic instability on arrival in the operating room
  • Hypotension on arrival in the operating theatre: Systolic blood pressure < 100 mmHg or Mean arterial pressure < 65 mmHg
  • Hypertension on arrival at the operating theatre: Systolic blood pressure > 160 mmHg or Mean arterial pressure > 100 mmHg
  • Adult under guardianship, curatorship or safeguard of justice
  • Unable to give consent
  • Pregnant or breastfeeding woman
  • Emergency surgery (cannot be delayed by 24 hours)
  • Current participation in an interventional protocol that interferes with the evaluation criteria of the study
  • Not affiliated to or not benefiting from a social security scheme
  • Lack of informed and written consent from the patient
  • Patient with a dilated aorta with a risk of rupture (e.g. chronic dissection for example)
  • Patient with severe aortic insufficiency
  • Treated hypertensive history that may have hypersensitivity to noradrenaline and hypertensive flares hypertensive attacks

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

211 participants in 2 patient groups

Noradrenaline
Experimental group
Description:
Noradrenaline diluted to 16µg/ml infused at 0.06g/kg/min by peripheral venous line from the start of peripheral venous line from the start of preoxygenation
Treatment:
Drug: noradrenaline
Standard care
No Intervention group
Description:
standard care

Trial contacts and locations

1

Loading...

Central trial contact

VOURC'H Mickael, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems